Blueprint Medicines: Q2 Earnings Insights


Blueprint Medicines BPMC reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM.

Here's what investors need to know about the announcement.


Blueprint Medicines missed estimated earnings by 20.18%, reporting an EPS of $-2.68 versus an estimate of $-2.23.

Revenue was up $9.25 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.15 which was followed by a 0.7% increase in the share price the next day.

Here's a look at Blueprint Medicines's past performance:


Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate -1.94 -1.65 -1.63 -1.86
EPS Actual -1.79 -0.99 -2 -1.86
Revenue Estimate 36.65M 102.69M 42.47M 19.01M
Revenue Actual 62.73M 107.02M 24.19M 27.30M

To track all earnings releases for Blueprint Medicines visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!